Euroapi

Euroapi CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Euroapi (EAPI.PA) as of Nov 4, 2026 is 62.55 %. In the previous year, CapEx to Operating Cash Flow Ratio was 87.88 % — a change of -28.82% (lower).

CapEx/OCF

62.55 %

YoY

-28.82%

Last updated:

CapEx to Operating Cash Flow Ratio of Euroapi is 2025 62.55 % . CapEx to Operating Cash Flow Ratio of Euroapi was 2024 87.88 % . It decreases by -28.82% lower compared to the previous year.

The Euroapi CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2019
234.38 EUR
Jan 1, 2020
91.32 EUR
Jan 1, 2021
123.92 EUR
Jan 1, 2022
373.66 EUR
Jan 1, 2023
2,603.92 EUR
Jan 1, 2024
87.88 EUR
Jan 1, 2025
62.55 EUR
The Euroapi CapEx/OCF history
YEARCapEx/OCFYoY
62.55 %-28.82%
87.88 %-96.63%
2,603.92 %+596.87%
373.66 %+201.54%
123.92 %+35.69%
91.32 %-61.04%
234.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Euroapi Stock analysis

What does Euroapi do? Euroapi SA generates revenue by manufacturing and supplying active pharmaceutical ingredient solutions to healthcare companies. The company develops and produces vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids, hormones, anti-infectives, opiates including morphine, codeine, and thebaine, as well as analgesics. It offers Contract Development and Manufacturing Organization (CDMO) services through its Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones, and Opiates & Controlled Substances technologies. Healthcare partners purchase these products and services, with production sites across France, the United Kingdom, Germany, Italy, and Hungary supporting the supply chain. The company’s primary customers are healthcare companies seeking active pharmaceutical ingredient solutions. These clients buy products like vitamin B12, prostaglandins, and opiates, as well as CDMO services such as Microbial Fermentation and Steroids and Hormones development. Euroapi SA’s revenue streams are derived from both the direct sale of active ingredients and the provision of specialized manufacturing services through its CDMO division. Euroapi SA’s business model relies on its global production network in five countries to deliver tailored pharmaceutical solutions. The firm’s portfolio includes high-demand molecules such as opioids (morphine, codeine, thebaine) and hormone-based treatments, which are supplied to healthcare partners through its CDMO services. This dual approach of product sales and service-based manufacturing ensures steady revenue from established pharmaceutical markets. Euroapi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Euroapi stock

CapEx to Operating Cash Flow Ratio of Euroapi is 62.55 % in 2025.

CapEx to Operating Cash Flow Ratio of Euroapi changed from 87.88 % to 62.55 %, representing a -28.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Euroapi since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Euroapi with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Euroapi

All Key Metrics — Euroapi